Literature DB >> 30290756

Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality.

Gulistan Bahat1, Asli Tufan2, Cihan Kilic1, Mehmet Akif Karan1, Alfonso J Cruz-Jentoft3.   

Abstract

AIM: Sarcopenia is recognized with its adverse functional outcomes. We aimed to report the prevalence of European Working Group on Sarcopenia in Older People (EWGSOP) defined sarcopenia and its individual components in community dwelling outpatient older adults and study the correlations of EWGSOP defined sarcopenia, muscle mass, muscle strength, and physical performance with functional status.
MATERIAL AND METHODS: The subjects were prospectively recruited from the geriatrics outpatient clinics of our university hospital. Body composition was assessed with bioimpedance analysis. Muscle strength was assessed by measurement of hand grip strength with hydraulic hand dynamometer, physical performance was assessed by 4 meter usual gait speed (UGS). Impaired muscle function was defined as presence of low muscle strength and or slow gait speed. As a measure of functionality, modified version of Katz activities of daily living (ADL) and Lawton instrumental activities of daily living (IADL) were assessed.
RESULTS: A total of 242 community dwelling outpatients with mean age of 79.4 ± 5.7 years were enrolled. 31.8% were male. Prevalence of low muscle mass was 2.1% and impaired muscle function was 71.1%. Prevalence of EWGSOP defined sarcopenia was 0.8% (1.3% in men and 0.6% in women). Most correlated parameter with ADL and IADL was the usual gait speed (r = 0.49, r = 0.63; p < .001, respectively). Grip strength was also correlated with ADL and IADL (r = 0.28, r = 0.35; p < .001). However, the skeletal muscle mass index (SMMI) was not correlated with ADL, IADL (p = .22, p = .22, respectively). In regression analysis, both ADL score and IADL scores were most related to UGS (beta = 0.5 and 0.6, p < .001), age (beta = -0.25 and -0.2, p < .001) and then sarcopenia (beta = 0.1 and 0.1, p < .05) but was not related to hand grip strength or SMMI.
CONCLUSIONS: The prevalence of sarcopenia was low as 0.8% albeit the presence of impaired muscle function in more than 2/3 of the cases. We have found that EWGSOP defined sarcopenia had association with ADL and IADL. The gait speed component of sarcopenia had the strongest associations with functional measures but SMMI component did not have any relation. We suggest that although low muscle mass may be a parameter related to worse functionality, it should not be regarded prerequisite for presence of sarcopenia analogous to low bone mineral density for osteoporosis.

Entities:  

Keywords:  EWGSOP; functionality; low muscle mass; muscle strength; sarcopenia

Mesh:

Year:  2018        PMID: 30290756     DOI: 10.1080/13685538.2018.1511976

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  19 in total

1.  Skeletal Muscle and Childhood Cancer: Where are we now and where we go from here.

Authors:  Chelsea G Goodenough; Robyn E Partin; Kirsten K Ness
Journal:  Aging Cancer       Date:  2021-05-20

2.  Screening for frailty and sarcopenia in community-dwelling older adults: a cross-sectional study from the Eastern Black Sea region of Turkey.

Authors:  Ulku Kezban Sahin; Elif Yeliz Tozluoglu; Habibe Durdu; Nurhayat Korkmaz; Nazmiye Tugba Bahar; Efsane Yavuz
Journal:  Aging Clin Exp Res       Date:  2022-06-15       Impact factor: 4.481

3.  Probable sarcopenia: associations with common geriatric syndromes and comorbidities in Turkish geriatric patients from a university hospital.

Authors:  Duygu Erbas Sacar; Cihan Kılıc; Meryem Merve Oren; Tugba Erdogan; Serdar Ozkok; Caglar Ozer Aydın; Nezahat Muge Catikkas; Mehmet Akif Karan; Gulistan Bahat
Journal:  Eur Geriatr Med       Date:  2022-08-27       Impact factor: 3.269

4.  Sarcopenic obesity is associated with impaired physical function and mortality in older patients with heart failure: insight from FRAGILE-HF.

Authors:  Hiroshi Saito; Yuya Matsue; Kentaro Kamiya; Nobuyuki Kagiyama; Daichi Maeda; Yoshiko Endo; Hidenao Ueno; Kenji Yoshioka; Akira Mizukami; Kazuya Saito; Yuki Ogasahara; Emi Maekawa; Masaaki Konishi; Takeshi Kitai; Kentaro Iwata; Kentaro Jujo; Hiroshi Wada; Masaru Hiki; Taishi Dotare; Tsutomu Sunayama; Takatoshi Kasai; Hirofumi Nagamatsu; Tetsuya Ozawa; Katsuya Izawa; Shuhei Yamamoto; Naoki Aizawa; Kazuki Wakaume; Kazuhiro Oka; Shin-Ichi Momomura; Tohru Minamino
Journal:  BMC Geriatr       Date:  2022-07-05       Impact factor: 4.070

5.  Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis.

Authors:  S K Papadopoulou; P Tsintavis; P Potsaki; D Papandreou
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

Review 6.  Sarcopenia: A Contemporary Health Problem among Older Adult Populations.

Authors:  Sousana K Papadopoulou
Journal:  Nutrients       Date:  2020-05-01       Impact factor: 5.717

7.  Effect of Resistance Training Under Normobaric Hypoxia on Physical Performance, Hematological Parameters, and Body Composition in Young and Older People.

Authors:  Alexander Törpel; Beate Peter; Lutz Schega
Journal:  Front Physiol       Date:  2020-04-28       Impact factor: 4.566

Review 8.  Muscle mass, strength, and physical performance predicting activities of daily living: a meta-analysis.

Authors:  Daniel X M Wang; Jessica Yao; Yasar Zirek; Esmee M Reijnierse; Andrea B Maier
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-12-01       Impact factor: 12.910

9.  Prevalence and risk factors of primary sarcopenia in community-dwelling outpatient elderly: a cross-sectional study.

Authors:  Visaratana Therakomen; Aisawan Petchlorlian; Narisorn Lakananurak
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

10.  Sex-specific differences in the prevalence of sarcopenia among pre-frail community-dwelling older adults in Saudi Arabia.

Authors:  Abdulaziz A Alodhayani
Journal:  Saudi J Biol Sci       Date:  2021-04-12       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.